Skip to main content

Table 1 Baseline Characteristics

From: Leptin, IL-6, and suPAR reflect distinct inflammatory changes associated with adiposity, lipodystrophy and low muscle mass in HIV-infected patients and controls

Variable

Atrophy (N = 10)

Hyper/Mix (N = 4 + 10)

Non-Lipo (N = 36)

Controls (N = 15)

Demography and lifestyle

Age (years)

50.1 (46.2; 47.5)

58.1 (54.0; 64.1)*

48.3 (40.1; 53.9)

47.6 (40.9; 62.3)

Smoking (N (%))

4 (40.0 %)

2 (14.3 %)

12 (33.3 %)

1 (6.7 %)*

Body composition

BMI (kg/m2)

21.1 (19.4; 24.1)*

27.2 (24.7; 29.3)

25.5 (23.2; 28.2)

25.4 (22.2; 29.7)

FMI (kg/m2)

2.4 (1.6; 3.2)*

5.4 (4.0; 7.1)

4.8 (3.6; 6.7)

4.8 (4.4; 7.5)

VAT (cm2)

136.7 (91.7; 160.4)

251.0 (178.9; 280.9)*

136.4 (96.8; 194.3)

120.2 (93.5; 159.8)

SAT (cm2)

105.5 (56.4; 129.1)*

254.8 (203.2; 294.6)

197.4 (152.1; 264.1)

253.5 (146.2; 310.9)

VAT/SAT

1.4 (1.1; 1.8)*

0.8 (0.7; 1.6)*

0.7 (0.5; 0.9)

0.5 (0.4; 0.8)

tLMI (kg/m2)

17.1 (15.7; 18.4)*

20.3 (18.4; 20.6)

18.4 (17.1; 20.6)

18.4 (18.0; 20.6)

lLMI (kg/m2)

5.5 (5.0; 6.6)

6.3 (6.0; 6.7)

6.1 (5.7; 6.7)

6.5 (6.2; 7.0)

Metabolism

Triglyceride

1.3 (1.1; 2.1)

1.4 (1.2; 2.4)

1.6 (1.0; 2.0)

0.9 (0.7; 1.1)*

Cholesterol

5.3 (4.6;6.4)

5.5 (4.8; 6.6)

5.4 (4.8; 6.4)

5.4 (4.7; 5.7)

HDL

1.4 (1.2; 1.5)

1.3 (1.0; 1.5)

1.3 (1.1; 1.5)

1.4 (1.3; 1.6)

VLDL

0.6 (0.5; 0.9)

0.5 (0.5; 0.9)

0.7 (0.5; 0.9)

0.4 (0.3; 0.5)*

LDL

3.2 (2.5; 4.2)

3.2 (2.7; 3.8)

3.4 (3.0; 4.5)

3.1 (2.6; 3.8)

HOMA-IR

0.9 (0.5; 1.2)

2.4 (1.6; 4.1)*

0.9 (0.5; 2.1)

0.5 (0.5; 1.3)*

Metabolic syndrome, N(%)

1 (10.0 %)

12 (85.7 %)*

14 (38.9 %)

2 (13.3 %)

HIV

HIV duration (years)

19.5 (17.8; 25.6)*

20.8 (16.5; 24.4)*

11.0 (4.9; 16.2)

-

cART duration (years)

15.3 (12.6; 18.4)*

15.2 (13.6; 16.3)*

5.8 (3.5; 13.0)

-

Current tNRTI

0 (0 %)

0 (0 %)

1 (2.8 %)

-

Previous tNRTI

9 (100.0 %)*a

14 (100.0 %)*

18 (53.0 %)a

-

HIV RNA ≤ 20 copies/mL

9 (90.0 %)

14 (100.0 %)

32 (88.9 %)

-

CD4+ T cells/μL

716 (569; 830)

593 (534; 910)

535 (393; 736)

739 (598; 880)*

CD8+ T cells/μL

1090 (802; 1160)

654 (583; 829)

821 (597; 1160)

397 (281; 493)*

CD4+:CD8+ ratio

0.7 (0.6; 0.8)

1.0 (0.7;1.3)

0.7 (0.5; 0.9)

1.9 (1.5; 3.0)*

  1. The table depicts median (25; 75 percentiles). *:p < 0.05 between groups and Non-Lipo. aPrevious treatment data missing from one patient in Atrophy and two patients in the Non-Lipo group
  2. Abbreviations: BMI body mass index, cART combination antiretroviral treatment, FMI fat mass index, HDL high density lipoprotein, HOMA-IR homeostatic model assessment of insulin resistance, IL-6 Interleukin 6, LDL low density lipoprotein, suPAR soluble urokinase plasminogen activator receptor, SAT subcutaneous adipose tissue, tNRTI thymidine nucleoside reverse transcriptase inhibitors, VAT Visceral adipose tissue, VLDL very low density lipoprotein
  3. We analysed differences between groups and Non-Lipo. Data were analysed using one-way Anova. BMI, FMI, HDL, SAT, triglycerides, VAT/SAT, VLDL, HOMA, and CD4 was analysed using Kruskal-Wallis test. Smoking, metabolic syndrome, previous tNRTI, and HIV RNA ≤ 20 copies/mL were analysed using Fisher’s exact test
Back to article page

Immunity & Ageing

ISSN: 1742-4933

Contact us